From Regenerative Science to Patients

Damage to the nervous system, whether caused by neurodegenerative disease or traumatic injury, remains largely irreversible with today’s treatments. At AdRegeneer, we develop therapies that aim to repair it. Our lead clinical program addresses multiple sclerosis (MS), where insufficient remyelination contributes to the progressive loss of function. Developed by our German subsidiary EpiGeneer GmbH, a transdermal patch delivering an HDAC2 activator is preparing to enter the clinic.